Climb Bio, Inc.
CLYM
Rank in Stocks
#9536
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Share Price
$9.78
Last synced: 2026-11-17
Market Cap
$782.70M
Change (1 day)
-1.61%
Change (1 year)
475.29%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Climb Bio, Inc. (CLYM)
Category
Healthcare
EPS for Climb Bio, Inc. (CLYM)
EPS as of September 2026 TTM: $-0.82
According to Climb Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-0.82. At the end of 2025 the company had an EPS of $-0.88, an increase over its 2024 EPS of $-1.53.
EPS history for Climb Bio, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.82 | -6.82% |
| 2025 | $-0.88 | -42.48% |
| 2024 | $-1.53 | 17.69% |
| 2023 | $-1.30 | -24.42% |
| 2022 | $-1.72 | -59.43% |
| 2021 | $-4.24 | 115.23% |
| 2020 | $-1.97 | 251.79% |
| 2019 | $-0.56 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,009.76% |
US
|
|
| $-7.08 | 763.41% |
US
|
|
| $-5.29 | 545.12% |
AU
|
|
| $21.56 | -2,729.27% |
NL
|
|
| $12.73 | -1,652.71% |
BE
|
Questions about Climb Bio, Inc.'s earnings per share (EPS)
What is Climb Bio, Inc.'s earnings per share (EPS)?
Climb Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-0.82, as of Sep 2026.
What was Climb Bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, Climb Bio, Inc.'s earnings per share (EPS) was $-0.88, compared with $-1.53 in 2024.
How has Climb Bio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Climb Bio, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.88) and lowest in 2021 ($-4.24).
How does Climb Bio, Inc.'s earnings per share (EPS) compare with similar companies?
Climb Bio, Inc.'s earnings per share (EPS) ($-0.82) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.